Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

berlin chemie / menarini bh d.o.o. sarajevo - олмесартана medoksomil - filmom obložena tableta - 20 mg/1 tableta - 1 filmom obložena tableta sadrži: 20 mg olmesartan medoksomil

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

berlin chemie / menarini bh d.o.o. sarajevo - олмесартана medoksomil - filmom obložena tableta - 40 mg/1 tableta - 1 filmom obložena tableta sadrži: 40 mg olmesartan medoksomil

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zentiva pharma d.o.o. - amlodipin, Индапамид, Периндоприл - tableta - 4 mg/1 tableta+ 1,25 mg/1 tableta+ 5 mg/1 tableta - 1 tableta sadrži: 4 mg perindopril erbumina (što odgovara 3,338 mg perindoprila), 1,25 mg indapamida i 5 mg amlodipina (što odgovara 6,934 mg amlodipin besilata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zentiva pharma d.o.o. - amlodipin, Индапамид, Периндоприл - tableta - 4 mg/1 tableta+ 1,25 mg/1 tableta+ 10 mg/1 tableta - 1 tableta sadrži: 4 mg perindopril erbumina (što odgovara 3,338 mg perindoprila), 1,25 mg indapamida i 10 mg amlodipina (što odgovara 13,868 mg amlodipin besilata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zentiva pharma d.o.o. - amlodipin, Индапамид, Периндоприл - tableta - 8 mg/1 tableta+ 2,5 mg/1 tableta+ 5 mg/1 tableta - 1 tableta sadrži: 8 mg perindopril erbumina (što odgovara 6,676 mg perindoprila), 2,5 mg indapamida i 5 mg amlodipina (što odgovara 6,934 mg amlodipin besilata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

zentiva pharma d.o.o. - amlodipin, Индапамид, Периндоприл - tableta - 8 mg/1 tableta+ 2,5 mg/1 tableta+ 10 mg/1 tableta - 1 tableta sadrži: 8 mg perindopril erbumina (što odgovara 6,676 mg perindoprila), 2,5 mg indapamida i 10 mg amlodipina (što odgovara 13,868 mg amlodipin besilata)

Europska Unija - hrvatski - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 i 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ptc therapeutics international limited - ataluren - mišićna distrofija, duchenne - ostali lijekovi za poremećaje mišićno-koštanog sustava - translarna indiciran za liječenje duchenneove mišićne distrofije mutacija u genu дистрофина delirijum, kod ambulantnih bolesnika u dobi od 2 i više godina. efikasnost nije bila dokazana u ne-ambulantnih pacijenata. prisutnost mutacija u genu дистрофина bred mora biti određena, genetičko testiranje.

Europska Unija - hrvatski - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Europska Unija - hrvatski - EMA (European Medicines Agency)

akcea therapeutics ireland limited - volanesorsen natrija - hyperlipoproteinemia type i - drugi гиполипидемические modificiranje - waylivra prikazan kao dodatak prehrani kod odraslih pacijenata s genetski potvrdio obiteljska chylomicronemia sindrom (dvs) i visok rizik za razvoj pankreatitis, u kojima je odgovor na prehrane i trigliceridi антигипертензивная terapija je bila neadekvatna.